
Tradename | Proper name | Company | Number | Date | Products |
|---|---|---|---|---|---|
| Menopur | menotropins | Ferring Pharmaceuticals | N-21663 RX | 2004-10-29 | 1 products |
Brand Name | Status | Last Update |
|---|---|---|
| menopur | Biologic Licensing Application | 2024-11-21 |
Code | Description |
|---|---|
| S0122 | Injection, menotropins, 75 iu |

Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Infertility | D007246 | EFO_0000545 | — | 20 | 24 | 54 | 66 | 81 | 237 |
| Female infertility | D007247 | EFO_0008560 | N97 | 10 | 3 | 9 | 6 | 24 | 49 |
| Polycystic ovary syndrome | D011085 | EFO_0000660 | E28.2 | 3 | 3 | 7 | 7 | 15 | 32 |
| Fertilization in vitro | D005307 | — | — | 1 | 3 | 3 | 10 | 9 | 25 |
| Ovulation induction | D010062 | — | — | 3 | 7 | 5 | 3 | 6 | 23 |
| Syndrome | D013577 | — | — | — | — | 1 | 3 | 12 | 16 |
| Hypogonadism | D007006 | — | E23.0 | 1 | 2 | 4 | 6 | 3 | 16 |
| Primary ovarian insufficiency | D016649 | EFO_0004266 | E28.3 | 4 | 4 | — | 1 | 9 | 15 |
| Assisted reproductive techniques | D027724 | — | — | — | — | 3 | 2 | 4 | 9 |
| Endometriosis | D004715 | EFO_0001065 | N80 | 2 | 1 | 1 | 1 | 4 | 8 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Pregnancy | D011247 | EFO_0002950 | Z33.1 | 1 | — | 1 | — | 9 | 11 |
| Male infertility | D007248 | EFO_0004248 | N46 | 1 | 1 | 3 | — | 4 | 8 |
| Helping behavior | D006379 | — | — | — | 1 | 5 | — | 1 | 7 |
| Ovarian hyperstimulation syndrome | D016471 | — | — | 1 | 1 | 1 | — | 2 | 5 |
| Azoospermia | D053713 | EFO_0000279 | N46.0 | — | 1 | 1 | — | 1 | 3 |
| Pituitary diseases | D010900 | — | E23.7 | — | — | 1 | — | 2 | 3 |
| Prostatic neoplasms | D011471 | — | C61 | 1 | 1 | 1 | — | 1 | 3 |
| Papillary thyroid cancer | D000077273 | — | — | — | 1 | 1 | — | — | 2 |
| Follicular adenocarcinoma | D018263 | — | — | — | 1 | 1 | — | — | 2 |
| Thyroid neoplasms | D013964 | EFO_0003841 | — | — | 1 | 1 | — | — | 2 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Premature menopause | D008594 | — | E28.31 | 2 | 2 | — | — | 7 | 9 |
| Premature birth | D047928 | EFO_0003917 | O60 | 1 | 1 | — | — | 3 | 4 |
| Endocrine system diseases | D004700 | EFO_0001379 | E34.9 | 1 | 1 | — | — | 2 | 3 |
| Leiomyoma | D007889 | — | D25 | 1 | 1 | — | — | 1 | 2 |
| Female genital diseases | D005831 | EFO_0009549 | N85 | — | 1 | — | — | 1 | 2 |
| Infections | D007239 | EFO_0000544 | — | 1 | 1 | — | — | — | 1 |
| Ectopic pregnancy | D011271 | — | O00 | 1 | 1 | — | — | — | 1 |
| Salpingitis | D012488 | — | N70.91 | 1 | 1 | — | — | — | 1 |
| Gonadal disorders | D006058 | — | — | 1 | 1 | — | — | — | 1 |
| Fertilization | D005306 | — | — | — | 1 | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Pharmacokinetics | D010599 | — | — | 2 | — | — | — | — | 2 |
| Area under curve | D019540 | — | — | 1 | — | — | — | — | 1 |
| Absorption | D000042 | — | — | 1 | — | — | — | — | 1 |
| Precocious puberty | D011629 | — | E22.8 | 1 | — | — | — | — | 1 |
| Delayed puberty | D011628 | — | E30.0 | 1 | — | — | — | — | 1 |
| Ovarian neoplasms | D010051 | EFO_0003893 | C56 | 1 | — | — | — | — | 1 |
| Therapeutic equivalency | D013810 | — | — | 1 | — | — | — | — | 1 |
| Vaccine immunogenicity | D000071497 | — | — | 1 | — | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Covid-19 | D000086382 | — | U07.1 | — | — | — | — | 4 | 4 |
| Neoplasms | D009369 | — | C80 | — | — | — | — | 3 | 3 |
| Oxidative stress | D018384 | EFO_1001905 | — | — | — | — | — | 3 | 3 |
| Congenital abnormalities | D000013 | EFO_0003915 | Q89.9 | — | — | — | — | 2 | 2 |
| In vitro oocyte maturation techniques | D059471 | — | — | — | — | — | — | 2 | 2 |
| Ovarian cysts | D010048 | — | N83.1 | — | — | — | — | 2 | 2 |
| Post-acute covid-19 syndrome | D000094024 | — | — | — | — | — | — | 2 | 2 |
| Ovarian pregnancy | D065172 | — | O00.2 | — | — | — | — | 1 | 1 |
| Oogenesis | D009866 | — | — | — | — | — | — | 1 | 1 |
| Myofibroma | D047708 | — | — | — | — | — | — | 1 | 1 |
| Drug common name | Menotropins |
| INN | _ |
| Description | Menotropin (also called human menopausal gonadotropin or hMG) is a hormonally active medication for the treatment of fertility disturbances. Frequently the plural is used as the medication is a mixture of gonadotropins. Menotropins are extracted from the urine of postmenopausal women.
|
| Classification | Protein |
| Drug class | atropine derivatives |
| Image (chem structure or protein) | ![]() |
| Structure (InChI/SMILES or Protein Sequence) | — |
| PDB | — |
| CAS-ID | 61489-71-2 |
| RxCUI | — |
| ChEMBL ID | CHEMBL2108427 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | DB00032 |
| UNII ID | 5Y9QQM372Q (ChemIDplus, GSRS) |






